Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Corsica Health vs Direct Meds

Corsica Health
Graded #188

Lower grade

vs+16.299999999999997
Direct Meds
Graded #19

Higher grade

The verdict

Direct Meds takes it — 82.6/100 to 66.3/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +37
48
85
Dose & formulationDirect Meds +11
77
88
Clinical oversightCorsica Health +7
87
80
Labs & monitoringDirect Meds +24
54
78
FulfillmentDirect Meds +5
75
80
Contract termsDirect Meds +25
55
80
Corsica Health · left barDirect Meds · right bar

The numbers

MetricCorsica HealthDirect Meds
WeighScore66.3/10082.6/100
GradeCB−
Scorecard rank#188#19
Semaglutide$249/mo (compounded)$179/mo
Tirzepatide$349/mo (compounded)$224/mo
CoverageCoverage not publishedNot publicly listed
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Corsica Health

Graded #188 · C

Strengths

  • Public pricing shown for both compounded and brand-name options — a real transparency advantage
  • $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
  • LegitScript Certified
  • Clear 3-step intake: Assessment, Provider Review, Receive Medication
  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced

Where it loses points

  • Legal entity name and state of incorporation not disclosed on the site
  • Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
  • Per-state availability not listed publicly
  • First-month promotional pricing not disclosed
  • Lab-work inclusion not clearly disclosed
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard